Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Armel, Stockis"'
Autor:
Mika Naganawa, Jean-Dominique Gallezot, Sjoerd J. Finnema, Ralph Paul Maguire, Joël Mercier, Nabeel B. Nabulsi, Sophie Kervyn, Shannan Henry, Jean-Marie Nicolas, Yiyun Huang, Ming-Kai Chen, Jonas Hannestad, Henrik Klitgaard, Armel Stockis, Richard E. Carson
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Background Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the hu
Externí odkaz:
https://doaj.org/article/22d2f1f3be124f3691b641c2f77893e1
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::679146b57869a54fd9a5edbd5e767fcb
https://doi.org/10.1002/cpdd.1264
https://doi.org/10.1002/cpdd.1264
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 52(2)
We characterised the bioavailability, safety, and tolerability of brivaracetam 100 mg intravenous bolus and 15-min infusion versus oral reference tablet in 24 healthy Japanese participants.In this randomised, open-label, three-period crossover study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bef3ef17e3b22765b3696b2a4e6814
https://pubmed.ncbi.nlm.nih.gov/35293287
https://pubmed.ncbi.nlm.nih.gov/35293287
Autor:
Paul Martin, Joël Mercier, Jean-Marie Nicolas, Mika Naganawa, Armel Stockis, Yiyun Huang, Samantha Rossano, Christian Otoul, Sjoerd J. Finnema, Yihuan Lu, Richard E. Carson, Takuya Toyonaga, Nabeel Nabulsi, Steven De Bruyn, R. Paul Maguire, Jim Ropchan
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism. 40:1890-1901
11C-UCB-J is a positron emission tomography (PET) radioligand that has been used in humans for synaptic vesicle glycoprotein 2A (SV2A) imaging and as a potential synaptic density marker. The centrum semiovale (CS) is a proposed reference region for n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d7f7dc915bfdc57b51e32236479da6b
https://doi.org/10.1177/0271678x19879230
https://doi.org/10.1177/0271678x19879230
Publikováno v:
Paediatric Drugs
Objective This trial evaluated the short-term safety and tolerability, steady-state pharmacokinetics, and preliminary efficacy of brivaracetam oral solution in children aged 1 month to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58dbeaa2bb4382484008c646e421e838
http://europepmc.org/articles/PMC6682562
http://europepmc.org/articles/PMC6682562
Autor:
Jean-Marie Nicolas, Jonas Hannestad, Steven DeBruyn, Samantha Rossano, Yiyun Huang, Sjoerd J. Finnema, Mika Naganawa, Rafal M. Kaminski, Nabeel Nabulsi, Pierandrea Muglia, Christian Otoul, Hong Gao, Paul Martin, Joël Mercier, Henrik Klitgaard, Richard E. Carson, Armel Stockis, Shannan Henry, Richard Pracitto, David Matuskey, Sophie Kervyn, Ralph Paul Maguire
Publikováno v:
Epilepsia
Summary Objective Brivaracetam (BRV) and levetiracetam (LEV) are antiepileptic drugs that bind synaptic vesicle glycoprotein 2A (SV2A). In vitro and in vivo animal studies suggest faster brain penetration and SV2A occupancy (SO) after dosing with BRV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c8cac6fb964e16978fdb45714dd6ca
https://doi.org/10.1111/epi.14701
https://doi.org/10.1111/epi.14701
Publikováno v:
Epilepsy Research. 149:13-16
A combined adult and pediatric population pharmacokinetic model including covariate effects was developed; simulations were subsequently performed to guide intravenous pediatric dosing adaptations. Two pharmacokinetic trials with sparse blood samplin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9211c7fb1829b537fa08e71200d6e1
https://doi.org/10.1016/j.eplepsyres.2018.10.011
https://doi.org/10.1016/j.eplepsyres.2018.10.011
Publikováno v:
The Journal of Clinical Pharmacology. 59:541-547
A pediatric population pharmacokinetic model including covariate effects was developed using data from 2 clinical trials in pediatric patients with epilepsy (SP0847 and SP1047). Lacosamide plasma concentration-time data (n = 402) were available from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af14a58aa099ddee578468b8d140a5dd
https://doi.org/10.1002/jcph.1340
https://doi.org/10.1002/jcph.1340
Autor:
Benoit Culot, Armel Stockis, E. Bourgogne, Sylvie Dell'Aiera, Jean-Marie Nicolas, Hugues Chanteux
Publikováno v:
Journal of Chromatography B. 1086:138-145
Brivaracetam (BRV) is a new high affinity synaptic vesicle protein 2A ligand recently approved for adults with partial-onset seizures. As a support to in vitro metabolism assays, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method coup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48ca767ca05e65cf5fe2bc4ee81801a3
https://doi.org/10.1016/j.jchromb.2018.04.018
https://doi.org/10.1016/j.jchromb.2018.04.018
Publikováno v:
Epilepsy Research. 137:95-100
Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A, recently approved as adjunctive therapy in the treatment of focal (partial-onset) seizures in patients 16 years of age and older with epilepsy. The goal of the present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b04939ca5b65c60d7e2d26811f8cbb
https://doi.org/10.1016/j.eplepsyres.2017.09.014
https://doi.org/10.1016/j.eplepsyres.2017.09.014